Page 23 - IMO-2-3

Innovative Medicines & Omics Progress in antivenom therapy

Another area of advancement lies in the use of small- regulatory harmonization for new products. Furthermore,
molecule enzyme inhibitors that directly target venom WHO has established a global antivenom prequalification
toxins. Compounds, such as varespladib and batimastat program aimed at ensuring the quality, safety, and
11
have been shown in preclinical models to neutralize venom effectiveness of antivenoms through rigorous review and
activity by inhibiting enzymatic components critical quality control standards. This initiative seeks not only
to tissue damage and systemic toxicity. Varespladib, in to rebuild market confidence but also to ensure equitable
particular, is a potent inhibitor of secretory PLA (sPLA₂), access to high-quality products in affected regions.
2
a major component of many elapid and viperid venoms. In sum, while traditional antivenoms remain
Its small molecular size and potential for oral or parenteral
administration make it a promising candidate for field- essential tools in snakebite management, ongoing
based, first-line intervention before definitive antivenom scientific advancements are paving the way toward more
administration. Such adjunctive therapies may not only rational, scalable, and patient-centered therapies. The
improve survival rates but also reduce the required integration of recombinant biotechnology, small-molecule
antivenom dose, thereby diminishing the risk of adverse pharmacology, nanomedicine, and synthetic vaccinology
reactions and treatment costs. represents a paradigm shift that, if successfully translated
into clinical practice, could dramatically improve outcomes
Advancements in nanotechnology have also opened for snakebite victims worldwide.
new possibilities for the development of antivenom
12
alternatives. Nanoparticles, such as liposomes and 5. Ongoing clinical trials
dendrimers are being explored as vehicles for delivering Numerous clinical trials registered on ClinicalTrials.gov
toxin-binding ligands or as scaffolds for detoxifying agents. and other international platforms are actively investigating
These nanoscale platforms can be tailored to enhance advanced therapeutic strategies to improve the treatment
tissue penetration, prolong circulation time, and improve of snakebite envenomation. These efforts reflect a
stability under ambient conditions—features particularly
valuable in resource-limited settings where cold-chain global commitment to modernizing antivenom therapy,
logistics are a major barrier to effective care. expanding beyond traditional polyclonal antibody-based
products to encompass a broad spectrum of innovative
Synthetic epitope-based vaccines represent a preventive modalities. The diversity of these clinical studies highlights
strategy that diverges from reactive treatment paradigms. the growing complexity and scientific depth of the field.
By identifying conserved immunogenic regions across
venom toxins, researchers aim to develop immunogens One of the most notable advancements in this domain
capable of eliciting protective immune responses in humans, is the investigation of small molecule inhibitors, such as
thereby conferring immunity against envenomation. varespladib-methyl, an oral sPLA₂ inhibitor. The Phase
While still in early experimental phases, such vaccines 2 clinical trial, NCT04996264 is currently evaluating its
14
could revolutionize snakebite management in high-risk safety, tolerability, and efficacy in envenomated patients.
occupational or geographic populations, especially in areas This molecule has shown promise as a broad-spectrum
with limited access to healthcare. neutralizer of venom activity in preclinical studies, offering
the potential to be used as a pre-referral intervention in
Despite the promise of these innovations, several rural or remote settings where access to healthcare is
obstacles remain. Regulatory pathways for novel biologics, limited and delays in treatment are common (Table 2).
particularly in low- and middle-income countries, can
be lengthy and inconsistent. Substantial investment is Another interventional study, NCT04470791, conducted
also needed to support clinical trials assessing the safety, in Mexico, is examining the use of localized cryotherapy as a
efficacy, and cost-effectiveness of these emerging therapies supplementary approach to standard antivenom treatment
15
compared to traditional antivenoms. Moreover, stakeholder in patients with Bothrops envenomation. Cryotherapy
coordination—including governments, manufacturers, may reduce local inflammation and tissue necrosis, which
academic institutions, and NGOs—is critical to ensure are common complications associated with viperid bites. If
these technologies reach the populations most in need. successful, this strategy could be incorporated into clinical
practice to improve functional outcomes and reduce the
In response to these complex challenges, the WHO has
launched a global strategy to halve the number of snakebite need for surgical interventions, such as debridement or
amputation.
deaths and disabilities by 2030. This strategy includes a
13
commitment to supporting research and development In terms of observational research, trial NCT04520282
of next generation antivenoms, promoting the use of aims to measure hemostatic parameters in patients
standardized preclinical efficacy testing, and facilitating suffering from venom-induced consumption coagulopathy,

Volume 2 Issue 3 (2025) 17 doi: 10.36922/IMO025240026